Company Description
Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions in the United States and internationally.
It operates through two segments: Prevention and Recovery, and Reconstructive segments. The company’s Prevention and Recovery segment offers orthopedic solutions and recovery sciences including rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals.
Its Reconstructive segment operates surgical implant business, which includes a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger, as well as surgical productivity tools.
It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy.
It distributes its products through independent distributors and directly under the ESAB and DJO brands.
The company was formerly known as Colfax Corporation. Enovis Corporation was founded in 1995 and is headquartered in Wilmington, Delaware.
| Country | United States |
| Founded | 1995 |
| IPO Date | May 8, 2008 |
| Industry | Specialty Industrial Machinery |
| Sector | Industrials |
| Employees | 7,367 |
| CEO | Matthew Trerotola |
Contact Details
Address: 2711 Centerville Road, Suite 400 Wilmington, Delaware 19808 United States | |
| Phone | 302 252 9160 |
| Website | enovis.com |
Stock Details
| Ticker Symbol | ENOV |
| Exchange | NYSE |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001420800 |
| CUSIP Number | 194014502 |
| ISIN Number | US1940145022 |
| Employer ID | 54-1887631 |
| SIC Code | 3842 |
Key Executives
| Name | Position |
|---|---|
| Matthew L. Trerotola | Chief Executive Officer and Chairman |
| Phillip Benjamin Berry | Senior Vice President and Chief Financial Officer |
| Patricia A. Lang | Senior Vice President and Chief Human Resources Officer |
| Daniel A. Pryor | Executive Vice President of Strategy and Business Development |
| Brady R. Shirley | Executive Advisor and Director |
| John Kleckner | Vice President, Controller and Chief Accounting Officer |
| Kyle William Rose | Vice President of Investor Relations |
| Bradley J. Tandy J.D. | Senior Vice President and Chief Legal Officer |
| Katie Sweet | Vice President of Corporate Communication |
| Tim Czartoski | President of U.S. Surgical and Global Product and Enabling Technologies |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 14, 2025 | 8-K | Current Report |
| Feb 26, 2025 | 10-K | Annual Report |
| Feb 26, 2025 | 8-K | Current Report |
| Feb 26, 2025 | 8-K | Current Report |
| Feb 14, 2025 | SCHEDULE 13G | Filing |
| Feb 7, 2025 | SCHEDULE 13G/A | Filing |
| Feb 6, 2025 | SCHEDULE 13G | Filing |
| Feb 5, 2025 | SCHEDULE 13G | Filing |
| Jan 28, 2025 | 8-K | Current Report |
| Jan 28, 2025 | 424B7 | Filing |